The people advancing quantitative neuroscience
Our team brings together expertise across neuroscience, neuroimaging, statistics, medicine, and large-scale data science — united by a shared mission to make the brain measurable.
Kelly is a product and strategy leader with over a decade of experience at the intersection of neuroscience, AI, and precision medicine. She was an early employee and senior product leader at Octave Bioscience, where she helped scale AI-enabled neurology diagnostics to nationwide clinical adoption and played a central role in portfolio strategy, commercialization, and fundraising. At Centile, Kelly will lead company and product strategy as we build and scale a clinically impactful neuroimaging platform.
Ariana is a healthcare technology leader who is devoted to building technology that transforms how healthcare works in the real world. She brings that same commitment to rigorous, impactful science to everything we build at Centile Bio. Ariana has deep expertise at the intersection of medical imaging, machine learning, and scalable cloud infrastructure, and has led large-scale imaging technology initiatives across academic medicine and national research consortia. Ariana holds a Ph.D. from the University of Pennsylvania, with deep roots in neuroimaging and computational modeling.Before joining the team, Ariana built and shipped AI-powered systems for pediatric cancer research at the Children's Hospital of Philadelphia (Center for Data-Driven Discovery in Biomedicine) — from automated tumor segmentation to cloud-scale data pipelines processing tens of thousands of clinical imaging exams across hospitals nationwide. She has a proven track record of bridging the gap between research and production, leading multidisciplinary teams, and navigating the real-world complexity of clinical data standards, privacy, and infrastructure.
Andrew Van is a Senior Machine Learning Engineer at Centile Bioscience, where he applies his expertise in neuroimaging and ML to advance data-driven diagnostics for brain diseases and disorders across the lifespan. He brings deep experience at the intersection of machine learning and medical imaging, most recently serving as Senior Machine Learning Scientist at Turing Medical, where he led R&D efforts behind two FDA-cleared neurosurgical software products. Andrew holds a PhD in Bioengineering from Washington University in St. Louis, where his research on precision brain mapping methods contributed to publications in Nature, PNAS, and Neuron. He also holds patents in real-time MRI motion monitoring and distortion correction, and has a track record of translating research into production-grade clinical tools.
Anna has a PhD in AI for Medical Imaging and was a research fellow at AIM-Harvard MGB, KannLab, and Brigham and Women’s Hospital. Her work focuses on medical imaging, with broader interests in pediatric brain imaging, computer vision, machine learning, and causality.
Founder and CEO of Alva10, an advisory firm established in March 2016, and Managing Partner of 10Edison, a diagnostics-focused venture fund. Specializes in creating partnerships between payers and diagnostic companies to enhance the value of diagnostic technology. Harvard University MS.
Regius Professor of Psychiatry at King's College London and Emeritus Professor at the University of Cambridge. Pioneer of network analytics in human neuroscience and former VP of Experimental Medicine at GlaxoSmithKline. King’s College London PhD, University of Oxford MD.
